On April 21, FDA issued a warning letter citing, among other defects, "similar color schemes (including a distinct orange), design layouts and other presentation elements" between two disease state websites and the company's website for their prescription drug.
A month later, a DDMAC letter cited a web video's "audio and visual elements" fading out before risk information was presented.
The FDA is planning to provide guidance on Internet-based promotion - but you can't go offline while waiting for them to do so. So how can you focus your compliance efforts where they will do the most good, especially when FDA's enforcement targets include website colors and online video editing techniques?
Click here for more information, or to register for this Aug. 10 webinar!
